65 related articles for article (PubMed ID: 10950800)
41. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?
Boomer JS; Green JM; Hotchkiss RS
Virulence; 2014 Jan; 5(1):45-56. PubMed ID: 24067565
[TBL] [Abstract][Full Text] [Related]
42. From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.
Abad C; Safdar N
Curr Infect Dis Rep; 2012 Oct; 14(5):540-50. PubMed ID: 22903847
[TBL] [Abstract][Full Text] [Related]
43. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.
Bo L; Wang F; Zhu J; Li J; Deng X
Crit Care; 2011; 15(1):R58. PubMed ID: 21310070
[TBL] [Abstract][Full Text] [Related]
44. Severe community-acquired pneumonia and PIRO: a new paradigm of management.
Rello J; Lisboa T; Wunderink R
Curr Infect Dis Rep; 2009 Sep; 11(5):343-8. PubMed ID: 19698277
[TBL] [Abstract][Full Text] [Related]
45. Immunomodulation in the critically ill.
Webster NR; Galley HF
Br J Anaesth; 2009 Jul; 103(1):70-81. PubMed ID: 19474216
[TBL] [Abstract][Full Text] [Related]
46. Melioidosis: epidemiology, pathophysiology, and management.
Cheng AC; Currie BJ
Clin Microbiol Rev; 2005 Apr; 18(2):383-416. PubMed ID: 15831829
[TBL] [Abstract][Full Text] [Related]
47. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome.
Adhikari N; Burns KE; Meade MO
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004477. PubMed ID: 15495113
[TBL] [Abstract][Full Text] [Related]
48. Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial.
Schaefer H; Engert A; Grass G; Mansmann G; Wassmer G; Hubel K; Loehlein D; Ulrich BC; Lippert H; Knoefel WT; Hoelscher AH
Ann Surg; 2004 Jul; 240(1):68-75. PubMed ID: 15213620
[TBL] [Abstract][Full Text] [Related]
49. Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis.
Cheng AC; Dasari P; Currie BJ
Eur J Clin Microbiol Infect Dis; 2004 Mar; 23(3):205-7. PubMed ID: 14986161
[TBL] [Abstract][Full Text] [Related]
50. Ethical problems of evaluating a new treatment for melioidosis.
Cheng AC; Lowe M; Stephens DP; Currie BJ
BMJ; 2003 Nov; 327(7426):1280-2. PubMed ID: 14644975
[TBL] [Abstract][Full Text] [Related]
51. Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?
Azoulay E; Delclaux C
Intensive Care Med; 2004 Jan; 30(1):10-7. PubMed ID: 14593456
[TBL] [Abstract][Full Text] [Related]
52. Pathogenesis of pneumococcal pneumonia in cyclophosphamide-induced leukopenia in mice.
Wang E; Simard M; Ouellet N; Bergeron Y; Beauchamp D; Bergeron MG
Infect Immun; 2002 Aug; 70(8):4226-38. PubMed ID: 12117931
[TBL] [Abstract][Full Text] [Related]
53. A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia.
Hartmann P; Lammertink J; Mansmann G; Hübel K; Salzberger B; Stützer H; Engert A; Fätkenheuer G
Eur J Med Res; 2005 Jan; 10(1):29-35. PubMed ID: 15737951
[TBL] [Abstract][Full Text] [Related]
54. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
56. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
57. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia.
Nelson S; Heyder AM; Stone J; Bergeron MG; Daugherty S; Peterson G; Fotheringham N; Welch W; Milwee S; Root R
J Infect Dis; 2000 Sep; 182(3):970-3. PubMed ID: 10950800
[TBL] [Abstract][Full Text] [Related]
58. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.
Root RK; Lodato RF; Patrick W; Cade JF; Fotheringham N; Milwee S; Vincent JL; Torres A; Rello J; Nelson S;
Crit Care Med; 2003 Feb; 31(2):367-73. PubMed ID: 12576938
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
